Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 3rd GBHI in Amsterdam: lively discussions and intensive exchange with authorities Meet us in Amsterdam: 3rd GBHI Conference starts soon (12 – 13 April 2018) Meet us in Munich: AGAH Annual Meeting 26 – 27 April 2018 Regorafenib: first in human as eye drops 3rd GBHI conference – all speakers confirmed 1st GBHI-Conference – Conference Report now available Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Oncological patients Design development Bioavailability Bioequivalence Cardiovascular surveillance Endpoint Clinical development program Spacious archive Gynaecological trials Dose linearity Ocular tolerability ADAM Subcontractor qualification Edema Standard operating procedure Data Management Plan Patient recruitment Feasibility MDI Hypothalamic Ophthalmological trials Hormone replacement therapy Expert DUS Uveitis Phase IIa trials Sore throat CDM GCP training GLP Inhalatives CRF Sensitisation trials PAES Dermal irritation Efficacy Metered dose inhaler Absorption windows First in human Clinical Monitoring Xerostomia Pharmacology Protocol development SDV Postmenopausal women IVIVC OTC Drug Food Interaction Degeneration CDSIC FDA Pulse oximetry plethysmography Healthy subjects Training Charcoal Drug Drug Interaction US FDA Authorities Allergy HPA axis Phase I Dry eye Dry powder inhaler DDI Statistical services COPD SocraTec C&S Protocol Phase III Non interventional Centralised procedure Project Management Pharmacodynamic studies Absorption ANVISA Clinical trials Network Female adolescents Clinical study Transdermal therapeutic system SOP based Children IEC Steady state Patch Central surveillance system NIS Quality Assurance CRO Biometrics Pilot study Local tolerability Product development Sequential designs Early phase Informed Consent Procedure Inspection Pituitary Biopharmaceutics Elpro Highly variable drugs Quality Phase IIb trials Monitoring Axis CDASH Patients Audit Consultancy Thuringia Eye disease Sample size estimation MCID Slit lamp microscopy Oncologic network Referral system In vitro in vivo correlation HTA CRA EMA Immunogenicity Macular Copyright DPI Scientific advice Patch adhesion Source Data Verification Data management Phase IV MMM Lung Scientific expertise Clinical pharmacology unit ICF WinNonlin Rhine Main area Ophthalmologist Phase I Unit Experience SAS Biosimilars Legal representative Statistical Analysis Plan Standardisation Biopharmaceutical Cough Statistical programming Contraception Pragmatism FIM Competence Database GCP Good Clinical Practice Legal Information Adrenocortical Ovulation inhibition Recruitment rates IB Data Validation Plan Investigators brochure CDISC Oncology Common cold US CFR 21 Part 11 Asthma IMPD Creativity Post authorisation Pharmacokintetics Safety Auditing Life cycle management Glaucoma Intensive assessment station Quality Management System DFI Anaesthesiologist AGAH Ophthalmology TTS Pharmacokinetics Paediatricians HRT Phase II PASS  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page